From migraine to chronic daily headache: The biological basis of headache transformation

Headache

Volumn 47, Issue 8, 2007, Pages 1251-1258

  Meng, Ian D ^a,c   Cao, Ling ^b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Chronic daily headache; Episodic migraine; Migraine

Indexed keywords

FLUOROCITRIC ACID; MORPHINE; OPIATE; PARACETAMOL; PROPENTOFYLLINE; TRIPTAN DERIVATIVE;

CHRONIC DAILY HEADACHE; DISEASE COURSE; DOWN REGULATION; DRUG INDUCED HEADACHE; DRUG USE; DRUG WITHDRAWAL; GENETICS; GLIA CELL; HEADACHE; HUMAN; MIGRAINE; NEUROIMMUNOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SENSITIZATION; SENSORY NERVE; STRESS;

CHRONIC DISEASE; DISEASE PROGRESSION; HEADACHE DISORDERS, SECONDARY; HUMANS; MIGRAINE DISORDERS; PAIN; RISK FACTORS; STRESS;

EID: 34648815041     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00907.x     Document Type: Review

References (132)

1. Lipton RB, et al. Classification of primary headaches. Neurology 2004 63 (3 427 435.
2. Spierings EL, et al. Chronic daily headache: A time perspective. Headache. 2000 40 : 306 310.
3. Bigal ME, et al. Chronic migraine is an earlier stage of transformed migraine in adults. Neurology. 2005 65 (10 1556 1561.
4. Scher AI, et al. Prevalence of frequent headache in a population sample. Headache. 1998 38 (7 497 506.
5. Scher AI, et al. Risk factors for chronic daily headache. Curr Pain Headache Rep. 2002 6 (6 486 491.
6. Rapoport A, et al. Analgesic rebound headache in clinical practice: Data from a physician survey. Headache. 1996 36 (1 14 19.
7. Mathew NT. Chronic refractory headache. Neurology. 1993 43 (6 Suppl 3 S26 33.
8. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006 46 (9 1334 1343.
9. Scher AI, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003 106 (1-2 81 89.
10. Fanciullacci M, De Cesaris F. Preventing chronicity of migraine. J Headache Pain. 2005 6 (4 331 333.
11. Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol. 2006 95 (3 1298 1306.
12. Coffey RJ, Rhoton AL. Pain-Sensitive Cranial Structures. Oxford University Press 1993.
13. Ray BS, Wolff HG. Experimental studies on headache pain sensitive structures of the head and their significance in headache. Arch. Surg. 1940 41 : 813 856.
14. Strassman AM, et al. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996 384 (6609 560 564.
15. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003 4 (5 386 398.
16. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 199 5 : 159 177.
17. Levy D, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007.
18. Zhang X, et al. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther. 2007.
19. Levy D, et al. Mast cell involvement in the pathophysiology of migraine headache: A hypothesis. Headache. 2006 46 (Suppl 1 S13 18.
20. Kemper RH, et al. Migraine and function of the immune system: A meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia. 2001 21 (5 549 557.
21. Pradalier A, Launay JM. Immunological aspects of migraine. Biomed Pharmacother. 1996 50 (2 64 70.
22. Covelli V, et al. Are TNF-alpha and IL-1 beta relevant in the pathogenesis of migraine without aura? Acta Neurol (Napoli). 1991 13 (2 205 211.
23. Heatley RV, et al. Increased plasma histamine levels in migraine patients. Clin Allergy. 1982 12 (2 145 149.
24. Gazerani P, et al. A correlation between migraine, histamine and immunoglobulin e. Scand J Immunol. 2003 57 (3 286 290.
25. Covelli V, et al. Alterations of nonspecific immunity in patients with common migraine. J Clin Lab Anal. 1990 4 (1 9 15.
26. Mazaheri S, et al. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura. J Neurol. 2006 253 (12 1589 1593.
27. Hermann GE, et al. TNF(alpha) modulation of visceral and spinal sensory processing. Curr Pharm Des. 2005 11 (11 1391 1409.
28. Juhasz G, et al. NO-induced migraine attack: Strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003 106 (3 461 470.
29. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996 16 (6 412 418.
30. Olesen J, et al. Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain. Neuroreport. 1993 4 (8 1027 1030.
31. Olesen J, et al. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994 15 (5 149 153.
32. Iversen H, et al. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain. 1989 38 : 17 24.
33. Theoharides TC, et al. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005 49 (1 65 76.
34. Dimitriadou V, et al. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience. 1991 44 (1 97 112.
35. Rozniecki JJ, et al. Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. Brain Res. 1999 849 (1-2 1 15.
36. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001 89 : 107 110.
37. Burstein R, et al. The development of cutaneous allodynia during a migraine attack: Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000 123 : 1703 1709.
38. Burstein R, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000 47 (5 614 624.
39. Ren K, Dubner R. Central nervous system plasticity and persistent pain. J Orofac Pain. 1999 13 (3 155 163 discussion 164-171.
40. McMahon SB, et al. Immune and glial cell factors as pain mediators and modulators. Exp Neurol. 2005 192 (2 444 462.
41. Willis WD. Long-term potentiation in spinothalamic neurons. Brain Res Brain Res Rev. 2002 40 (1-3 202 214.
42. Wieseler-Frank J, et al. Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005 14 (4 166 174.
43. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science. 2000 288 (5472 1765 1769.
44. Papandreou O, et al. Serum S100beta protein in children with acute recurrent headache: A potentially useful marker for migraine. Headache. 2005 45 (10 1313 1316.
45. Marchand F, et al. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005 6 (7 521 532.
46. De Leo JA, et al. The tetrapartite synapse: Path to CNS sensitization and chronic pain. Pain. 2006 122 (1-2 17 21.
47. Tsuda M, et al. P2'4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003 424 (6950 778 783.
48. Tanga FY, et al. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A. 2005 102 (16 5856 5861.
49. Meng ID, Porreca F. Mechanisms of medication overuse headache. Headache Currents. 2004 1 : 47 54.
50. Raskin NH, et al. Headache may arise from perturbation of brain. Headache. 1987 27 (8 416 420.
51. Tortorella P, et al. Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. J Neurol Sci. 2006 244 (1-2 137 141.
52. Gee JR, et al. The association of brainstem lesions with migraine-like headache: An imaging study of multiple sclerosis. Headache. 2005 45 (6 670 677.
53. Weiller C, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 1 (7 658 660.
54. Welch KM, et al. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001 41 (7 629 637.
55. Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci U S A. 1999 96 (14 7687 7692.
56. Ossipov MH, et al. Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci. 2000 909 : 12 24.
57. Porreca F, et al. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J Neurosci. 2001 21 (14 5281 5288.
58. Gardell LR, et al. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci. 2003 23 (23 8370 8379.
59. Kincaid W, et al. Role for medullary pain facilitating neurons in secondary thermal hyperalgesia. J Neurophysiol. 2006 95 (1 33 41.
60. Pertovaara A, et al. Chronic spinal nerve ligation induces changes in response characteristics of nociceptive spinal dorsal horn neurons and in their descending regulation originating in the periaqueductal gray in the rat. Exp Neurol. 1997 147 (2 428 436.
61. Pertovaara A, et al. Lidocaine in the rostroventromedial medulla and the periaqueductal gray attenuates allodynia in neuropathic rats. Neurosci Lett. 1996 218 (2 127 130.
62. Fields HL, et al. Central Nervous System Mechanisms of Pain Modulation, Elsevier: Churchill Livingstone 2005.
63. Raghavendra V, et al. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci. 2004 20 (2 467 473.
64. Zwart JA, et al. Analgesic use: A predictor of chronic pain and medication overuse headache: The Head-HUNT Study. Neurology. 2003 61 (2 160 164.
65. Zwart JA, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004 62 (9 1540 1544.
66. Mathew NT, et al. Transformation of episodic migraine into daily headache: Analysis of factors. Headache. 1982 22 (2 66 68.
67. Kudrow L. Cluster headache. Clinical, mechanistic, and treatment aspects. Panminerva Med. 1982 24 (1 45 54.
68. Limmroth V, Katsarava Z. Medication overuse headache. Curr Opin Neurol. 2004 17 (3 301 306.
69. Pageler L, et al. Medication-overuse headache. Curr Pain Headache Rep. 2005 9 (6 430 435.
70. Limmroth V, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002 59 (7 1011 1014.
71. Bahra A, et al. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003 43 (3 179 190.
72. Wilkinson SM, et al. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 41 (3 303 309.
73. Silverman K, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med. 1992 327 (16 1109 1114.
74. Peters GA, Horton BT. Headache: With special reference to the excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc. 1951 26 (9 153 161.
75. Ossipov MH, et al. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005 80 (2-3 319 324.
76. Colpaert FC. System theory of pain and of opiate analgesia: No tolerance to opiates. Pharmacol Rev. 1996 48 (3 355 402.
77. Laulin JP, et al. Opiate tolerance to daily heroin administration: An apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 1999 89 (3 631 636.
78. Laulin JP, et al. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci. 1998 10 (2 782 785.
79. Ossipov MH, et al. Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sci. 2003 73 (6 783 800.
80. Belanger S, et al. Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience. 2002 115 (2 441 453.
81. Menard DP, et al. A calcitonin gene-related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia. J Neurosci. 1996 16 (7 2342 2351.
82. Gardell LR, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002 22 (15 6747 6755.
83. Harari Y, et al. The effect of morphine on mast cell-mediated mucosal permeability. Surgery. 2006 139 (1 54 60.
84. Stankiewicz E, et al. Mast cells are responsible for the lack of anti-inflammatory effects of morphine in CBA mice. Mediators Inflamm. 2004 13 (5-6 365 368.
85. Kolaczkowska E, et al. Critical role of mast cells in morphine-mediated impairment of zymosan-induced peritonitis in mice. Inflamm Res. 2001 50 (8 415 421.
86. King T, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005 116 (3 276 288.
87. Mao J, et al. Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002 22 (18 8312 8323.
88. Kest B, et al. The NMDA receptor antagonist MK-801 protects against the development of morphine tolerance after intrathecal administration. Proc West Pharmacol Soc. 1993 36 : 307 310.
89. Ben-Eliyahu S, et al. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 1992 575 (2 304 308.
90. Marek P, et al. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 1991 547 (1 77 81.
91. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991 251 (4989 85 87.
92. Gutstein HB, Trujillo KA. MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 1993 626 (1-2 332 334.
93. Mao J, et al. Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci. 1994 14 (4 2301 2312.
94. Bilsky EJ, et al. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain. 1996 68 (2-3 229 237.
95. Manning BH, et al. Continuous co-administration of dextromethorphan or MK-801 with morphine: Attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 1996 67 (1 79 88.
96. Larcher A, et al. Acute tolerance associated with a single opiate administration: Involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience. 1998 84 (2 583 589.
97. Celerier E, et al. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 1999 847 (1 18 25.
98. Celerier E, et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology. 2000 92 (2 465 472.
99. Celerier E, et al. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J Neurosci. 2001 21 (11 4074 4080.
100. Lai J, et al. Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci. 2006 9 (12 1534 1540.
101. Meng ID, Harasawa I. Chronic morphine exposure increases the proportion of on-cells in the rostral ventromedial medulla in rats. Life Sci. 2007 80 (20 1915 1920.
102. Johnston IN, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004 24 (33 7353 7365.
103. Watkins LR, et al. Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci. 2005 28 (12 661 669.
104. Raghavendra V, et al. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci. 2002 22 (22 9980 9989.
105. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res. 2001 39 (3 281 286.
106. Tawfik VL, et al. Transcriptional and translational regulation of glial activation by morphine in a rodent model of neuropathic pain. J Pharmacol Exp Ther. 2005 313 (3 1239 1247.
107. Raghavendra V, et al. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology. 2004 29 (2 327 334.
108. Cui Y, et al. Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res. 2006 1069 (1 235 243.
109. Chakravarty A. Chronic daily headaches: Clinical profile in Indian patients. Cephalalgia. 2003 23 (5 348 353.
110. Lipton RB, Bigal ME. Migraine: Epidemiology, impact, and risk factors for progression. Headache. 2005 45 (Suppl 1 S3 S13.
111. Nash JM, Thebarge RW. Understanding psychological stress, its biological processes, and impact on primary headache. Headache. 2006 46 (9 1377 1386.
112. Bodnar RJ. Neuropharmacological and neuroendocrine substrates of stress-induced analgesia. Ann N Y Acad Sci. 1986 467 : 345 360.
113. Terman GW, Liebeskind JC. Relation of stress-induced analgesia to stimulation-produced analgesia. Ann N Y Acad Sci. 1986 467 : 300 308.
114. Imbe H, et al. Stress-induced hyperalgesia: Animal models and putative mechanisms. Front Biosci. 2006 11 : 2179 2192.
115. Costa A, et al. Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. Neurosci Lett. 2005 383 (1-2 7 11.
116. da Silva Torres IL, et al. Long-lasting delayed hyperalgesia after chronic restraint stress in rats-effect of morphine administration. Neurosci Res. 2003 45 (3 277 283.
117. Suarez-Roca H, et al. Role of mu-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. Behav Brain Res. 2006 167 (2 205 211.
118. Pielsticker A, et al. Impairment of pain inhibition in chronic tension-type headache. Pain. 2005 118 (1-2 215 223.
119. Staud R, et al. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain. 2003 101 (1-2 167 174.
120. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997 13 (3 189 196.
121. Julien N, et al. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005 114 (1-2 295 302.
122. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997 70 (1 41 51.
123. Maier SF. Bi-directional immune-brain communication: Implications for understanding stress, pain, and cognition. Brain Behav Immun. 2003 17 (2 69 85.
124. Theoharides TC, et al. Stress-induced intracranial mast cell degranulation: A corticotropin-releasing hormone-mediated effect. Endocrinology. 1995 136 (12 5745 5750.
125. Reuter U, et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol. 2002 51 (4 507 516.
126. Nair A, Bonneau RH. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol. 2006 171 (1-2 72 85.
127. Rivat C, et al. Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats. Neuropsychopharmacology 2007.
128. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006 67 (2 252 257.
129. Bigal ME, et al. Obesity and migraine: A population study. Neurology. 2006 66 (4 545 550.
130. Alexandraki K, et al. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006 1084 : 89 117.
131. Van Houdenhove B, et al. The role of life stress in fibromyalgia. Curr Rheumatol Rep. 2005 7 (5 365 370.
132. Thompson D, et al. Fibromyalgia: An overview. Curr Psychiatry Rep. 2003 5 (3 211 217.